Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT201 in Advanced Gynecological Tumors
NCT06191900Terminated
- Sponsor
- Grit Biotechnology
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Open-label, single-arm trial of GT201 in Cervical Cancer (CC), sponsored by Grit Biotechnology. Primary endpoint: Adverse Events at 3 years. Started Jun 2023; status: terminated.
02
Drugs
GT201
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06191900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191900.